A Conversation with F. Randy Vogenberg About the Future of Infection Prevention After COVID-19

Amid escalating multidrug-resistant organism threats, hospitals face business risks and patient trust erosion, necessitating improved cleaning and infection prevention practices.

The role of infection preventionists (IPs) has evolved significantly over 75 years, from early surveillance of nosocomial infections to becoming data-driven experts navigating pandemics like COVID-19.

Media in the US presents AI as both beneficial and risky. Positive coverage shows AI's potential through virtual assistants like Siri, while cautionary tales warn of misuse like misinformation and deepfakes. How does all this work in health care?

In the ongoing fight against COVID-19, the FDA has granted Emergency Use Authorization for Pemgarda, a COVID-19 infusion drug. Read on for more.

Four years ago today, March 15, 2020, the COVID-19 lockdown began, and since then, the world has undergone significant changes. It has been a terrifying experience for everyone, especially for the infection prevention community, both within and outside of the health care sector. However, a crucial question remains unanswered: What has the infection prevention community learned from this pandemic, and where does it go from here?

The CDC's recent decision to align recommendations for respiratory viruses, particularly COVID-19, has garnered support from the public and infectious disease societies. However, as the Infectious Diseases Society of America (IDSA) lends its backing to the CDC's harmonization efforts, concerns persist regarding the implications of this shift, especially considering the Omicron variant's unique characteristics and the ongoing challenges posed by COVID-19's multi-system impacts.